Literature DB >> 17994432

Subacute progression of human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Marco A Lima1, Ramza C Harab, Doris Schor, Maria J Andrada-Serpa, Abelardo Q C Araújo.   

Abstract

Although human T-lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is usually described as a chronic disabling disease, a rapid course over months or even weeks has been reported in some patients. The authors describe the clinical features of HAM/TSP in a Brazilian cohort and evaluate the prevalence of patients with a subacute progression of the disease. This was defined as the requirement of a wheelchair during the first 2 years after the onset of symptoms. Patients with this subacute course and patients with the chronic clinical course were compared in terms of their HTLV-I proviral loads (PLs) using real-time polymerase chain reaction (PCR). Seven out of 88 patients (7.9%) had a subacute progression. All patients were women and 5/7 acquired HTLV-I through sexual contact. There was no significant difference in the real-time PLs between the group with subacute evolution (mean 8.5 copies/100 cells, range 6.03 to 12.09) and those patients with a typical course of disease (mean 11.34 copies/100 cells, range 0.4 to 67.72) (P = .68), suggesting that factors other than the number of infected cells are implicated in the development of such an aggressive course of disease. Early recognition of this subgroup is important because immunosuppressive treatment might be beneficial if instituted promptly.

Entities:  

Mesh:

Year:  2007        PMID: 17994432     DOI: 10.1080/13550280701510096

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  35 in total

1.  Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP.

Authors:  M Nagai; K Usuku; W Matsumoto; D Kodama; N Takenouchi; T Moritoyo; S Hashiguchi; M Ichinose; C R Bangham; S Izumo; M Osame
Journal:  J Neurovirol       Date:  1998-12       Impact factor: 2.643

Review 2.  The HTLV-1 neurological complex.

Authors:  Abelardo Q C Araujo; Marcus Tulius T Silva
Journal:  Lancet Neurol       Date:  2006-12       Impact factor: 44.182

3.  Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation.

Authors:  O Gout; M Baulac; A Gessain; F Semah; F Saal; J Périès; C Cabrol; C Foucault-Fretz; D Laplane; F Sigaux
Journal:  N Engl J Med       Date:  1990-02-08       Impact factor: 91.245

4.  Incidence of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad.

Authors:  E M Maloney; F R Cleghorn; O S Morgan; P Rodgers-Johnson; B Cranston; N Jack; W A Blattner; C Bartholomew; A Manns
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-02-01

5.  HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression.

Authors:  Stéphane Olindo; Agnès Lézin; Philippe Cabre; Harold Merle; Martine Saint-Vil; Mireille Edimonana Kaptue; Aïssatou Signate; Raymond Césaire; Didier Smadja
Journal:  J Neurol Sci       Date:  2005-10-15       Impact factor: 3.181

6.  Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study.

Authors:  Stéphane Olindo; Philippe Cabre; Agnes Lézin; Harold Merle; Martine Saint-Vil; Aissatou Signate; Mickael Bonnan; Aurelie Chalon; Lionel Magnani; Raymond Cesaire; Didier Smadja
Journal:  Arch Neurol       Date:  2006-11

7.  Pathology of chronic myelopathy associated with HTLV-I infection (HAM/TSP).

Authors:  Y Iwasaki
Journal:  J Neurol Sci       Date:  1990-04       Impact factor: 3.181

Review 8.  An HTLV-I vaccine: why, how, for whom?

Authors:  G de Thé; R Bomford
Journal:  AIDS Res Hum Retroviruses       Date:  1993-05       Impact factor: 2.205

9.  Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom.

Authors:  J K Cruickshank; P Rudge; A G Dalgleish; M Newton; B N McLean; R O Barnard; B E Kendall; D H Miller
Journal:  Brain       Date:  1989-08       Impact factor: 13.501

Review 10.  Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I).

Authors:  A Gessain; O Gout
Journal:  Ann Intern Med       Date:  1992-12-01       Impact factor: 25.391

View more
  9 in total

1.  Common γ-chain blocking peptide reduces in vitro immune activation markers in HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Raya Massoud; Yoshimi Enose-Akahata; Yutaka Tagaya; Nazli Azimi; Asjad Basheer; Steven Jacobson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-17       Impact factor: 11.205

2.  Early neurologic abnormalities associated with human T-cell lymphotropic virus type 1 infection in a cohort of Peruvian children.

Authors:  Emily A Kendall; Elsa González; Iván Espinoza; Martín Tipismana; Kristien Verdonck; Daniel Clark; Sten H Vermund; Eduardo Gotuzzo
Journal:  J Pediatr       Date:  2009-07-22       Impact factor: 4.406

3.  Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis.

Authors:  Yoshihisa Yamano; Tomoo Sato
Journal:  Front Microbiol       Date:  2012-11-09       Impact factor: 5.640

4.  Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity.

Authors:  Tomoo Sato; Naoko Yagishita; Keiko Tamaki; Eisuke Inoue; Daisuke Hasegawa; Misako Nagasaka; Hiroko Suzuki; Natsumi Araya; Ariella Coler-Reilly; Yasuhiro Hasegawa; Yoshio Tsuboi; Ayako Takata; Yoshihisa Yamano
Journal:  Front Microbiol       Date:  2018-07-25       Impact factor: 5.640

5.  NMOSD-like and longitudinal extensive HTLV1-associated myelitis are extremes that flank an overlooked continuum.

Authors:  Mickael Bonnan; Stéphane Olindo; Aissatou Signate; Quentin Lobjois; Maeva Stephant; Dalia Dimitri Boulos; Philippe Cabre
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-07-31

6.  Following the Clues: Usefulness of Biomarkers of Neuroinflammation and Neurodegeneration in the Investigation of HTLV-1-Associated Myelopathy Progression.

Authors:  Flávia Dos Santos Souza; Nicole Lardini Freitas; Yago Côrtes Pinheiro Gomes; Rafael Carvalho Torres; Juliana Echevarria-Lima; Isaac Lima da Silva-Filho; Ana Claudia Celestino Bezerra Leite; Marco Antonio Sales Dantas de Lima; Marcus Tulius Teixeira da Silva; Abelardo de Queiroz Campos Araújo; Otávio Melo Espíndola
Journal:  Front Immunol       Date:  2021-10-26       Impact factor: 7.561

7.  Spastic Paraparesis After SARS-CoV-2 Infection Without Radiological Changes.

Authors:  Sanela Zukic; Ena Topcic; Renata Hodzic; Osman Sinanovic; Mirjana Vidovic
Journal:  Cureus       Date:  2022-03-11

8.  Human T-lymphotropic Virus Type I (HTLV-I) Proviral Load and Clinical Features in Iranian HAM/TSP Patients: Comparison of HTLV-I Proviral Load in HAM/TSP Patients.

Authors:  Rosita Vakili; Faezeh Sabet; Sanaz Aahmadi; Reza Boostani; Houshang Rafatpanah; Ali Shamsian; S A Rahim Rezaee
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

9.  Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P).

Authors:  Junji Yamauchi; Kenichiro Tanabe; Tomoo Sato; Masanori Nakagawa; Eiji Matsuura; Yoshio Tsuboi; Keiko Tamaki; Hirokuni Sakima; Satoshi Ishihara; Yuki Ohta; Naoki Matsumoto; Kenichi Kono; Naoko Yagishita; Natsumi Araya; Katsunori Takahashi; Yasuo Kunitomo; Misako Nagasaka; Ariella Coler-Reilly; Yasuhiro Hasegawa; Abelardo Araujo; Steven Jacobson; Maria Fernanda Rios Grassi; Bernardo Galvão-Castro; Martin Bland; Graham P Taylor; Fabiola Martin; Yoshihisa Yamano
Journal:  Viruses       Date:  2022-01-12       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.